Supply of the product Panvax Pandemic Influenza Vaccine by CSL Ltd

Overview

The Therapeutic Goods Act 1989, enacted by the Parliament of Australia, aims to regulate the safety, quality, and efficacy of therapeutic goods within the country. This legislation fills a critical gap by establishing a robust framework for the approval, monitoring, and surveillance of therapeutic goods, thereby ensuring they meet necessary standards to protect public health. The Act was designed to address issues related to the safety and quality of therapeutic goods by providing the Therapeutic Goods Administration (TGA) with the authority to control the import, supply, and distribution of these goods. In this context, the TGA’s policy objective is to safeguard public health by ensuring that therapeutic goods available in Australia are of acceptable quality and safety. On 5 February 2014, a delegate of the Secretary of the Department of Health authorised an exemption for CSL Ltd’s supply of the Panvax Pandemic Influenza Vaccine (Split Virion, Inactivated, Adjuvanted) AUST R 137704 from certain microbial standards stipulated in Therapeutic Goods Order No. 77. This exemption, granted under sections 14 and 14A of the Therapeutic Goods Act 1989, allows the vaccine to not comply with the preservative efficacy testing requirement for Staphylococcus aureus at 6 and 24 hours, subject to specific conditions. This decision reflects the TGA’s role in balancing public health protection with the practicalities of vaccine production and distribution, particularly in the context of pandemic preparedness.

Scope and Application

The Therapeutic Goods Act 1989, as applied in this case, pertains to the regulation of therapeutic goods within Australia. Specifically, section 14 and 14A of the Act allow for the exemption of certain products from compliance with particular standards under the Therapeutic Goods Orders. In this instance, the Act applies to CSL Ltd, a company located in Parkville, Victoria, and its product, the Panvax Pandemic Influenza Vaccine. The exemption granted by a delegate of the Secretary of the Department of Health pertains to the microbial standards for medicines, specifically relating to the efficacy of antimicrobial preservation of the medicine. This exemption is limited to non-compliance with preservative efficacy testing for Staphylococcus aureus at 6 and 24 hours, and the product is not expected to undergo testing at 6 hours but must meet the "No Increase" requirement at 24 hours as per the European Pharmacopoeia and British Pharmacopoeia standards. The exemption applies indefinitely and is subject to conditions specified under section 15(1) of the Act. The application of this Act is nationwide, affecting the conduct and transactions related to therapeutic goods across Australia.

Key Provisions

Sections 14 and 14A of the Therapeutic Goods Act 1989 permit the Secretary, or a delegate, to provide consent for certain therapeutic goods to be supplied in Australia, even if they do not conform to specified standards. In this instance, the delegate has consented to the supply of the Panvax Pandemic Influenza Vaccine by CSL Ltd, provided that it does not comply with the microbial standards outlined in Therapeutic Goods Order No. 77, specifically subsection 8 concerning the efficacy of antimicrobial preservation of medicines. This consent is granted under section 14(1) of the Act, which allows for the exemption of certain therapeutic goods from compliance with standards if it is in the public interest to do so. The consent is subject to conditions, as outlined under section 15(1) of the Act. The key condition is that the exemption from the microbial standards applies only to the non-compliance of preservative efficacy testing for Staphylococcus aureus at 6 and 24 hours. This means that while the product is exempt from the 6-hour testing requirement, it must still meet the "No Increase" requirement at 24 hours as per Eur.0153 Vaccines for Human Use and BP General Notice Vaccines. This exemption is intended to ensure that the vaccine remains effective against Staphylococcus aureus, even if it does not conform to the specified microbial standards in TGO 77. The Act imposes specific obligations on the parties involved. CSL Ltd, as the supplier of the vaccine, must ensure that the product supplied meets all other relevant requirements of the Act and any other applicable regulations or orders. The company must also maintain records and documentation that demonstrate compliance with the conditions of the consent granted by the delegate. Additionally, CSL Ltd must ensure that the vaccine is supplied in a manner that ensures the safety and efficacy of the product. There are potential consequences for breaches of the conditions or other obligations under the Act. While the Act does not explicitly state the penalties for non-compliance in this specific context, breaches of the Therapeutic Goods Act 1989 generally can lead to both civil and criminal penalties. Civil penalties may include fines, and in more serious cases, criminal penalties could apply, including imprisonment. The exact penalties depend on the nature and severity of the breach but can be significant, reflecting the importance of ensuring the safety and efficacy of therapeutic goods supplied in Australia.